Le Lézard
Classified in: Health
Subject: FEA

Implantica successfully performs cadaver implantations of pipeline products and several related tests at the cadaver lab


STOCKHOLM, Dec. 14, 2021 /PRNewswire/ -- Implantica AG (publ) announces today advances in development of its pipeline products at a cadaver lab in Germany.

Prototypes of several of the company's pipeline products have been implanted and tested in cadavers in order to determine key data points and advance development. The products that were tested include UriControl®, AppetiteControltm and UriRestore® as well as a new version of RefluxStoptm, which is designed to treat acid reflux in those patients undergoing a gastric sleeve procedure, representing approximately 600'000 procedures annually.

"Cadaver implantations provide us with key information and are an important step in furthering the product development process. I'm pleased to say that the prototype implantations of several of our pipeline products enhanced our knowledge and provided valueable input to our approval process. We continue our multiple pipeline workstreams and look forward to continue to bring products to market that have such a large impact on millions of people's lives," said Peter Forsell, CEO of Implantica.

For further information, please contact:

Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
[email protected]

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, [email protected]

The information was sent for publication, through the agency of the contact person set out above, on December 14, 2021 at 08:30 a.m. CET.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStoptm, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/implantica/r/implantica-successfully-performs-cadaver-implantations-of-pipeline-products-and-several-related-test,c3471634

The following files are available for download:

https://mb.cision.com/Main/19732/3471634/1509388.pdf

Implantica successfully performs cadaver implantations of pipeline products and several related tests at the cadaver lab


These press releases may also interest you

at 13:23
5 Ways Heart Health Care Can Improve
(Family Features) Before the advent of antibiotics, infectious diseases, such as pneumonia, tuberculosis and diphtheria, were the most common causes of death in the industrialized world. Today, heart disease is the leading cause of death in the...

at 13:23
How to Support Your Pet's Health During Summer
(Family Features) As a pet parent, you know your pet's needs are continually evolving. That's true during different stages of growth and even as the seasons change....

at 13:19
SHATTERPROOF AND ANTHEM BLUE CROSS AND BLUE SHIELD FOUNDATION PARTNER TO REDUCE HEALTHCARE STIGMA AROUND SUBSTANCE USE DISORDER
A substance use disorder (SUD) is a complex and often stigmatized health condition that affects countless individuals, families and communities. Stigma against people with a SUD extends beyond individual and interpersonal levels. The Shatterproof...

at 12:59
Myasthenia Gravis Foundation of America (MGFA) Kicks off Annual National MG Patient Conference With Program Announcements
More than 400 members of the myasthenia gravis (MG) rare disease community will come together this week at the MGFA National Patient Conference for support and a better understanding of how to manage their disease while learning about the latest...

at 12:36
Kedrion Announces Rare Disease Medicine RYPLAZIM® Now Available in US
Kedrion Biopharma Inc., an international biopharmaceutical company specializing in the research and development, production, and commercialization of plasma-derived therapeutic products used in treating rare and serious diseases, announced today that...

at 12:28
PANTHERx® Rare Partnering with X4 Pharmaceuticals Inc. for the Distribution of XOLREMDItm (mavorixafor), the First FDA-Approved Therapy Indicated for Use in Patients with WHIM Syndrome
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, today announced it was selected by X4 Pharmaceuticals, Inc. for the distribution of XOLREMDItm (mavorixafor), recently approved by the U.S....

More news about Health...


News published on and distributed by: